XBiotech Inc. (NASDAQ:XBIT – Get Free Report) saw a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 537,500 shares, an increase of 35.4% from the February 14th total of 397,000 shares. Based on an average trading volume of 36,700 shares, the days-to-cover ratio is presently 14.6 days. Approximately 2.7% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on XBiotech in a report on Thursday, February 15th. They issued a “sell” rating for the company.
View Our Latest Analysis on XBiotech
Institutional Investors Weigh In On XBiotech
XBiotech Trading Down 0.3 %
NASDAQ:XBIT opened at $6.31 on Thursday. XBiotech has a 12 month low of $3.05 and a 12 month high of $7.24. The stock has a 50 day moving average of $5.45 and a two-hundred day moving average of $4.61.
About XBiotech
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Further Reading
- Five stocks we like better than XBiotech
- 3 Warren Buffett Stocks to Buy Now
- 3 Small Dividend Paying Banks Insiders are Buying
- Basic Materials Stocks Investing
- 4 Oversold Large Cap Stocks Yielding High Dividends
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Big Investors Like What Comcast, Schwab, Alphabet Have to Offer
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.